“…Randomized, embedded, multifactorial, adaptive platform (REMAP) trials are well suited to ERAS protocols and can test multiple interventions simultaneously . Future trials will not only include patient clinical data and procedure information but genomics, pharmacogenetics, epigenetic data, and more . Patient-level pharmacogenetic data may ultimately be able to tell us the optimal drug regimen and optimal dosage of each drug to prescribe a given patient for anxiolysis, analgesia, anesthesia, and antiemetic prophylaxis based upon his or her unique genetic profile .…”